Dose-effect relationship of aripiprazole on hyperprolactinemia induced by risperidone in male patients
ZHANG Li-gang
LI Yan-li
LIU Yan
CHEN Jing-xu
LIU Yan-hong
ZHANG Rong-zhen
TAN Yun-long
YANG Fu-de
Abstract：Objective:To evaluate the dose effects of adjunctive treatment with aripiprazole on hyperprolactinemia in male patients who had been elevated prolactin levels because of risperidone treatment.Methods:58 cases with hyperprolactinemia induced by risperidonein male schizophrenic patients were randomly divided into four groups and received respectively aripiprazole 5 mg·d-1 (n =14),10 mg· d-1(n =14),20 mg· d-1(n =15) and placebo (n =15) added on to fixed dose risperidone treatment for 8 weeks.Serum prolactin levels (PRL) were measured at baseline,2,4 and 8 weeks.Results:At 8 weeks,all three aripiprazole doses resulted in significantly lower prolactin levels (P ＜ 0.01),while there was no significant difference in the placebo group (P ＞ 0.05) compared with the baseline.At the end of study,the decline and the normal ratio of PRL levels were significantly higher in three aripiprazole group than that in the placebo group (P ＜ 0.01),and significantly higher in 10 mg group,20 mg group than that in 5 mg group(P ＜ 0.05),but no significant difference between the 10 mg and 20 mg group (P ＞ 0.05).Conclusion:Aripiprazole may be effective for treating risperidone-induced hyperprolactinemia in male patients with schizophrenia,and the optimum dose for aripiprazole appears to be 10 mg·d-1.
Keywords：aripiprazolerisperidonehyperprolactinemiaschizophreniadose-effect relationship
Publication Date：2018-02-15
Online Publishing Date：2026-08-14(First online date of this platform, not the publication date of the document)
Pages：5( 334-338 )